|Articles|December 14, 2022
PHASTAR Joins Oncology Development Program (ODP2)
Advertisement
PHASTAR, has joined Lean Life Science’s Oncology Development Program (ODP2). The targeted program aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
Read more about the program
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting
2
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
3
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
4
Beyond Patient Centricity: What Rare Disease Research Gets Right
5